You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中藥股再度拉昇 隴神戎發(300534.SZ)連續第二日漲停
格隆匯12月21日丨延續昨日強勢,中藥股午後再度拉昇。隴神戎發拉昇封板,為連續第二日漲停,吉藥控股、紫鑫藥業、亞寶藥業、大理藥業、神奇藥業、漢森製藥、千金藥業、佛慈制藥等跟漲。貴州百靈上午已封漲停板。消息面上,國家中醫藥管理局在16日的新聞發佈會上稱,目前,新冠肺炎本土確診病例和無症狀感染者中,除個別特殊情況人員外,均普遍應用了中醫藥。中醫藥治療在改善患者臨牀症狀等方面發揮了重要作用。國家中醫藥管理局應對新冠肺炎疫情防控工作領導小組專家組副組長張忠德介紹,專家組經過綜合分析研判認為,本輪疫情仍屬於中醫“疫病”範疇,中醫的核心病因病機沒有大的改變,還是屬於濕毒鬱閉,中醫藥為主治療仍然有效。另外,醫保增加准入促進中醫藥發展。2021年11月1日起,廣西壯族自治區在國家藥品目錄892箇中藥飲片的基礎上,將廣西531箇中藥和民族藥飲片納入三項險種支付範圍;同時,將全區符合條件的118家中醫藥醫療機構納入醫保定點醫療機構管理範圍。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account